Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

ChEMBL compound–target relationships

1

Indexed connections · inspect this exact collection

FDA Drugs@FDA application records

124

Indexed connections · inspect this exact collection

FDA application actionJuly 9, 2010

Everolimus

Approved submission · SUPPL 5

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMay 13, 2010

Everolimus

Approved submission · SUPPL 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 20, 2010

Everolimus

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 30, 2009

Everolimus

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
Compound ↔ targetDate not supplied

EVEROLIMUS

INHIBITOR · CHEMBL1902

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →